WindMIL: T cell source is key

WindMIL is harnessing marrow-derived T cells to develop cell therapies for cancer

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens than CAR therapies engineered with peripheral blood T cells.

The company was founded in 2016 by Ivan Borrello, an associate professor of oncology at Johns Hopkins University School of Medicine, and Kimberly Noonan, who was an adjunct faculty member. She now serves as EVP and CSO

Read the full 702 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE